Charts
05 Dec, 2023
04 Dec, 2023
01 Dec, 2023
30 Nov, 2023
29 Nov, 2023
28 Nov, 2023
27 Nov, 2023
25 Nov, 2023
24 Nov, 2023
22 Nov, 2023
21 Nov, 2023
News
05 Dec, 2023
Gainers
Phio Pharma (NASDAQ:PHIO) shares moved upwards by 19.6% to $1.34 during Tuesday's after-market session. The market value of ...
13:40
FinancialContent
Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotech company aiming to address life-threatening and chronic aging-related conditions ...
01 Dec, 2023
30 Nov, 2023
21 Nov, 2023
16 Nov, 2023
15 Nov, 2023
14 Nov, 2023
17:27
FinancialContent
13:17
IBN Announces Latest Episode of The Bell2Bell Podcast featuring Wa’el Hashad, CEO of Longeveron Inc.
Yahoo! Finance
LOS ANGELES, Nov. 14, 2023 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The Bell2Bell Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The Bell2Bell Podcast delivers informative updates and exclusive interviews with executives operating in fast-moving industries. Bel
13 Nov, 2023
11 Nov, 2023
14:00
Yahoo! Finance
Extended Follow Up Data Show Continued, Transplant Free Survival of All Patients Results Support Continued Investigation of Lomecel-BTM As Adjunct to Stage II Surgery in HLHS - Enrollment ongoing in Phase 2 ELPIS II trial - MIAMI, Nov. 11, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical-stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syn
Longeveron Inc. (NASDAQ:LGVN) Q3 2023 Earnings Call Transcript November 10, 2023 Longeveron Inc. misses on earnings expectations. Reported EPS is $-0.28 EPS, expectations were $-0.24. Operator: Greetings, and welcome to the Longeveron’s Third Quarter 2023 Earnings call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal […]
10 Nov, 2023
12:33
Seeking Alpha
Top Line Results from CLEAR MIND Alzheimer’s disease Trial Affirm Safety Profile of Lomecel-B™ and Provide Efficacy Signal; Full Study Data Remains on Track to Share in Coming Weeks Long-term Survival Data from ELPIS 1 Trial to be Presented at the 2023 Scientific Sessions of the American Heart Association $4 Million in Equity Financing Secured in Registered Direct Offering ELPIS II Phase 2 Trial of Lomecel-B™ in HLHS Continues Enrollment; Completion of Study Enrollment Anticipated in 2024 Compan
Companies Reporting Before The Bell
• Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter.
• ...
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) released its 3Q earnings results: • Revenues of $200,000, which was slightly lower than last year due to completion of some grant-funded trials. • Earnings per share of -$0.28, which is in the range of what we were expecting. During 3Q 2023, Longeveron completed a direct offering of 2,424,243 shares and
09 Nov, 2023
Longeveron (NASDAQ:LGVN) is set to give its latest quarterly earnings report on Friday, 2023-11-10. Here's what investors need to know ...
06 Nov, 2023
03 Nov, 2023
12:00
Yahoo! Finance
MIAMI, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, announced today that it will report its third quarter 2023 financial results prior to the market open on Friday November 10, 2023. The Company will host a conference call and webcast that day to discuss the results, and provide an update on its clinical programs and corp
30 Oct, 2023
24 Oct, 2023
12:30
Yahoo! Finance
LOS ANGELES, Oct. 24, 2023 (GLOBE NEWSWIRE) -- via IBN -- Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announces that it has been featured in a broadcast via NetworkNewsAudio (“NNA”), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points
23 Oct, 2023
12:40
FinancialContent
Nations all over the world are getting older, but Japan is leading the charge, with nearly a third of its total population over 65 ...
16 Oct, 2023
13 Oct, 2023
20:05
Yahoo! Finance
MIAMI, Oct. 13, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced the closing of its previously announced registered direct offering, priced at-the-market under Nasdaq rules, for the purchase and sale of 2,424,243 shares of its
18:50
FinancialContent
Wa’el Hashad, CEO of Longeveron (NASDAQ: LGVN), was a guest recently on Benzinga’s All-Access.
Longeveron is a ...
12 Oct, 2023
Gainers
OpGen (NASDAQ:OPGN) stock increased by 513.1% to $2.06 during Thursday's pre-market session. The market value of their ...
12:00
Yahoo! Finance
MIAMI, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, today announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 2,424,243 of its shares of Class A common stock (“common stock"), or
09 Oct, 2023
Gainers
Acurx Pharmaceuticals (NASDAQ:ACXP) stock increased by 57.3% to $3.02 during Monday's regular session. The current volume of ...
Gainers
AnaptysBio (NASDAQ:ANAB) shares moved upwards by 17.9% to $22.7 during Monday's pre-market session. The market value of their ...
06 Oct, 2023
Gainers
RVL Pharmaceuticals (NASDAQ:RVLP) shares rose 19.5% to $0.13 during Friday's pre-market session. The company's market cap ...
05 Oct, 2023
Gainers
Orchard Therapeutics (NASDAQ:ORTX) shares increased by 96.5% to $15.99 during Thursday's regular session. As of 13:31 EST, ...
17:22
FinancialContent
Gainers
Orchard Therapeutics plc (NASDAQ: ORTX) shares climbed 97.7% to $15.98 after the company agreed to be acquired by ...
By Brad Sorensen, CFA NASDAQ:LGVN READ THE FULL LGVN RESEARCH REPORT Longeveron (NASDAQ:LGVN) announced results from its Phase 2a trial of its signature drug, Lomecel-B. The primary endpoint of the study of safety was met across all study groups. While this result is unabashedly positive, it was the observations of potential efficacy in treating Alzheimer’s that we were most interested in. The
Longeveron Inc(NASDAQ: LGVN) announced topline results from the Phase 2a trial of its investigational product Lomecel-B ...
Treatment derived from bone marrow shows promise in patients with mild Alzheimer's disease.
11:00
Yahoo! Finance
Company to Hold Conference Call & Webcast Today, October 5 at 8:00am ET Primary Endpoint of Safety Met Across all Study GroupsStatistical Significance Met for Secondary Endpoint Composite Alzheimer’s Disease Score (CADS) for Lomecel-B™ Low-Dose and for the Pooled Lomecel-B™ Treatment Group Relative to PlaceboOther Doses Demonstrated Numerical Slowing/Prevention of Disease Worsening Relative to Placebo Additional Biomarker Data Expected to be Announced in the Coming Weeks MIAMI, Oct. 05, 2023 (GL
29 Sep, 2023
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the iShares Micro-Cap ETF (IWC), we found that the implied analyst target price for the ETF based upon its underlying holdings is $152.54 per unit.
27 Sep, 2023
14 Sep, 2023
13:00
FinancialContent
BioRestorative Therapies Inc. (NASDAQ: BRTX) (“BioRestorative”) is a clinical-stage biotech company that is developing ...
12 Sep, 2023
11 Sep, 2023
14:54
FinancialContent
08 Sep, 2023
07 Sep, 2023
LOS ANGELES, Sept. 07, 2023 (GLOBE NEWSWIRE) -- via IBN – Longeveron Inc. (NASDAQ: LGVN), a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions, today announced it has selected the corporate communications expertise of IBN, a multifaceted financial news and publishing company for private and public entities, to assist with its investor communications. Longeveron’s research and therapies a
12:00
Yahoo! Finance
MIAMI, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today an abstract highlighting long-term survival data from the Company’s ELPIS 1 trial of Lomecel-B™ for patients with hypoplastic left heart syndrome
06 Sep, 2023
12:05
FinancialContent
Longeveron (NASDAQ: LGVN), a clinical-stage biopharma developing potential treatments for age-related and life-threatening diseases, is ...
05 Sep, 2023
12:00
Yahoo! Finance
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the Company’s management will be participating in the 25th Annual H.C. Wainwright Global Investment Conference, to be held September 11-13 ,
MIAMI, Sept. 05, 2023 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 62nd Emerging Growth Conference on September 6 & 7, 2023. The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth. Register for the conference here. Submit Questions for any of the presenting com
31 Aug, 2023
16:50
FinancialContent
Gainers
Acer Therapeutics Inc. (NASDAQ: ACER) shares jumped 145% to $1.4850 after Zevra Therapeutics announced it will acquire ...
U.S. stocks traded higher this morning, following the release of economic reports.
Following the market opening Thursday, the Dow ...
30 Aug, 2023
29 Aug, 2023
13:00
FinancialContent
Chronic back pain is a significant issue in the United States, affecting millions of individuals annually. According to experts, up to ...
12:00
Yahoo! Finance
MIAMI, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the Company’s management will be participating in the 149th Annual Conference of the National Investment Banking Association, to be held in Fo
22 Aug, 2023
MIAMI, Aug. 22, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN NASDAQ: LGVNR) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that the subscription period for its previously announced rights offering has begun. The subscription price is $3.00 per share. The subscription pe
16 Aug, 2023
MIAMI, Aug. 16, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that its registration statement previously filed with the Securities and Exchange Commission to conduct a tradable subscription rights offering has been declared
14 Aug, 2023
20:05
Yahoo! Finance
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing regenerative medicines for unmet medical needs, today announced it will host a virtual KOL Event on August 16, 2023 at 10:00 AM ET. Click here to register and attend. The event will feature Sunjay Kaushal, MD, PhD (Northwestern University Feinberg School of Medicine) and Ram Kumar Subramanyan, MD, PhD (Chief of Pediatric Cardiothoracic Surgery at
MIAMI, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) (“Longeveron” or “Company”), a clinical stage biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions such as hypoplastic left heart syndrome (HLHS), Alzheimer’s disease and Aging-related Frailty, announced today that it has filed an amended registration statement with the Securities and Exchange Commission to conduct a tradable subscription rights offering to holders of
12 Aug, 2023
11 Aug, 2023
20 Jul, 2023
12 May, 2023
13:52
Seeking Alpha
09 May, 2023
10 Apr, 2023
10 Mar, 2023
28 Feb, 2023
14 Nov, 2022
09 Oct, 2022
14 Sep, 2022
31 Aug, 2022
14 Aug, 2022
12 Aug, 2022
07 Jul, 2022
17 May, 2022
13 May, 2022
09 May, 2022
